Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane in Recurrent or Refractory Ovarian Cancer
NCT00261027Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jan 2003
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exemestane in epithelial ovarian cancer (EOC), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Objective Response Rate and Toxicities. Started Jan 2003; status: completed.
02
Drugs
exemestane
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT00261027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261027.